阿托伐他汀对慢性充血性心力衰竭氨基末端脑钠肽前体(NT-proBNP)水平及心功能的影响  

Atorvastatin-assisted therapy on NT-proBNP and cardiac function in chronic congestive heart failure

作　　者：苏学东[1] 缪素琼 汪桂花[1] 邓成英[1] 张琼[1] 谭涛[1] 王志刚[1] 杜丽霞[1] 

机构地区：[1]四川省乐山市市中区人民医院心血管内科,614000

出　　处：《中国现代药物应用》2013年第18期8-10,共3页Chinese Journal of Modern Drug Application

摘　　要：目的观察阿托伐他汀辅助治疗对慢性充血性心力衰竭患者氨基末端脑钠肽前体(NTproBNP)水平及心功能的影响。方法 CHF患者80例随机分为观察组和对照组各40例,两组均按照心功能分级给予相同的基础治疗,观察组在此基础上加用阿托伐他汀20 mg/d,每晚口服。结果治疗后14 d治疗组总有效率显著高于对照组(P<0.05)。观察组患者NT-proBNP与治疗前比较,差异均有统计学意义(P<0.05,);对照组NT-proBNP与治疗前比较,差异无统计学意义(P>0.05)。治疗后14 d,观察组NT-proBNP与治疗前比较与对照组比较差异均有统计学意义(P<0.05,0.01)。结论阿托伐他汀辅助治疗CHF,可进一步改善心功能,降低NT-pro BNP水平。Objective To observe the adjuvant treatment of atorvastatin on chronic congestive heart failure patients amino terminal pro-brain natriuretic peptide levels and cardiac function. Methods Two groups were in accordance with NYHA given the same basic treatment, observation group based on the use of atorvastatin 20 mg / d, orally night. Results After treatment, 14 clays treatment group was significantly higher （P〈0.05）. NT-proBNP observation group compared with before treatment compared with the control group were statistically significant differences （P〈0.05,0.01）. NT-proBNP control group compared with before treatment, the difference was not statistically significant （P〉 0.05）. Conclusion Atorvastatin adjuvant therapy CHF, lower NT- pro BNP levels.

关 键 词：慢性充血性心力衰竭 阿托伐他汀 氨基末端脑钠肽前体（NT-proBNP） 

分 类 号：R541.6[医药卫生—心血管疾病]